Ignite Creation Date:
2024-05-06 @ 7:50 PM
Last Modification Date:
2024-10-26 @ 3:15 PM
Study NCT ID:
NCT06155422
Status:
NOT_YET_RECRUITING
Last Update Posted:
2023-12-04
First Post:
2023-11-23
Brief Title:
A Prospective Real-world Study of Cadonilimab in Patients With Recurrent or Metastatic Cervical Cancer
Sponsor:
Gang Chen 101199
Organization:
Tongji Hospital
Study Overview
Official Title:
Efficacy and Safety of Cadonilimab PD-1CTLA-4 Bispecific Antibody in the Treatment of Recurrent or Metastatic Cervical Cancer a Multicenter Prospective Real-world Study
Status:
NOT_YET_RECRUITING
Status Verified Date:
2023-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This real-world study included all patients with recurrent or metastatic cervical cancer who used Cadonilimab in clinical practice regardless of treatment lines and combination with different treatments Through follow-up observations the aim of this study is to analyze the efficacy of Cadonilimab for recurrent or metastatic cervical cancer in the real world and to explore the differences in the efficacy of Cadonilimab in different stages of treatment as well as the efficacy of different treatment combinations so as to provide clinical evidence for the use of Cadonilimab for recurrent or metastatic cervical cancer
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None